Abstract
Obesity is a major risk factor for a wide range of cardiometabolic diseases, however the impact of specific aspects of body morphology remains poorly understood. We combined the GWAS summary statistics of fourteen anthropometric traits from UK Biobank through principal component analysis to reveal four major independent axes summarizing 99% of genetically driven variation in body shape and size: overall body size, adiposity, predisposition to abdominal fat deposition, and lean mass. Enrichment analyses suggest that body size and adiposity are affected by genes involved in neuronal signaling, whereas body fat distribution and lean mass are dependent on genes involved in morphogenesis and energy homeostasis. Using Mendelian randomization, we found that although both body size and adiposity contribute to the consequences of BMI, many of their effects are distinct, such as body size increasing the risk of diseases of the veins (b ≥ 0.044, p ≤ 8.9*10-10) and cardiac arrhythmia (b = 0.06, p = 4.2*10-17) while adiposity instead increased the risk of ischemic heart disease (b = 0.079, p = 8.2*10-21). The body mass-neutral component predisposing to abdominal fat deposition, likely reflecting a shift from subcutaneous to visceral fat, exhibited health effects that were weaker but specifically linked to lipotoxicity, such as ischemic heart disease (b = 0.067, p = 9.4*10-14) and diabetes (b = 0.082, p = 5.9*10-19). Combining their predicted effects significantly improved the prediction of obesity-related diseases, even when applied out-of-population (p < 10-10). The presented decomposition approach sheds light on the biological mechanisms underlying the remarkably heterogeneous nature of body morphology as well as its consequences on health and lifestyle.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has been conducted using the UK Biobank resource (#16389). The computations have been carried out on the HPC server of the Lausanne University Hospital. Z.K. was funded by the Swiss National Science Foundation (31003A-143914 and 310030-189147). B.D. is supported by the Swiss National Science Foundation (NCCR Synapsy, project grant Nr. 32003B_135679, 32003B_159780, 324730_192755 and CRSK-3_190185) and the Leenaards Foundation. LREN is very grateful to the Roger De Spoelberch and Partridge Foundations for their generous financial support. T.O.K. was funded by the Novo Nordisk Foundation (NNF17OC0026848, NNF18CC0034900).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was performed using the UK Biobank resource (#16389), which has been approved by the National Research Ethics Service Committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Switched from female-specific to combined-sex PC loadings; Issues with bi-directional MR and continuous health outcomes resolved; Added disease prediction; Manuscript streamlined and Methods clarified.
Data Availability
Data was provided by the UK Biobank and the Neale lab.
